Pars plana vitrectomy useful for post-injection endophthalmitis

Article

If improvement is not seen after 24 hours vitrectomy should be considered

Endophthalmitis is a serious threat to a patient's sight and can occur after any intraocular procedure. One such procedure that carries the risk of endophthalmitis is the administration of intravitreal injections. It has been reported that the risk of endophthalmitis post-injection can be as a result of the injection procedure itself or potentially as a result of drug contamination that may have occurred during preparation.

In all cases, early diagnosis and treatment of endophthalmitis is critical to avoid serious damage to the patient's visual acuity. However, the management of endophthalmitis that occurs after intravitreal injection has not been widely discussed and there are no guidelines set in place about the role of vitrectomy and silicone oil tamponade as treatment for this infection.

In a retrospective clinical study, Dr Pinarci and colleagues examined the records of just under 3000 patients who had been administered intravitreal injections between 2004 and 2011 at Baskent University Hospital. Out of this large group the team reviewed 8 patients (5 women and 3 men) who presented with acute endophthalmitis.

The initial treatment for all patients was a vitreous tap and intravitreal injections of both vancomycin and ceftazidime. In addition to this, topical antibiotics (vancomycin and ceftazidime) and an oral dose of moxifloxacin were also administered regularly. If this treatment did not improve the patient's symptoms or if they got any worse then they underwent pars plana vitrectomy with silicone oil tamponade.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.